Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 19, 2020
Daily News
October 19, 2020
- 3 Mega Pharma-Drugs Now Approved in Japan with Continuous Manufacturing, Japan Players Could Follow Suit Soon: PMDA Specialist
October 19, 2020
- Sakigake-Designated HAE Med Berotralstat, AZ’s Acalabrutinib Up for PAFSC Review on Oct. 30
October 19, 2020
- Japan’s Conditional Approval System for Regenerative Meds Is “Patient-Centered System”: PMDA Exec
October 19, 2020
- Fujifilm Eyes Avigan Use in Mild and Severe COVID-19 Cases: Exec
October 19, 2020
- Japan Needs to Consider Legal Positioning of Stable Drug Supply Rules: Official
October 19, 2020
- Chinese Regulators Accept Eisai’s Fycompa for Monotherapy, Additional Pediatric Use
October 19, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…